Literature DB >> 2646226

Susceptibility of new beta-lactams to the expanded-spectrum beta-lactamase CTX-1.

D Sirot1, C Chanal, R Labia, J Sirot.   

Abstract

Forty-three clinical isolates of enterobacteria were selected for the production of the new plasmid-mediated expanded-spectrum beta-lactamase CTX-1. The geometric means of MICs were ranged as follows: ticarcillin, greater than 4096 mg/l; ticarcillin + clavulanic acid (2 mg/l), 64-87 mg/l; LY 163892, 8.0-69.1 mg/l; cefotaxime, 5.7-26.4 mg/l; temocillin, 8.0-21.8 mg/l; Ro 158074, 4.0-18.7 mg/l aztreonam, 1.0-14.4 mg/l and BMY 28142, 1.4-2.8 mg/l. Moxalactam, imipenem and CM 40876 were resistant to hydrolysis and MICs were lower than 2.0 mg/l. A high protective effect on cefotaxime (MIC less than or equal to 0.5 mg/l) was obtained by sulbactam (4 mg/l). Escherichia coli transconjugants from each species showed similar levels of MICs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2646226     DOI: 10.1007/bf01643496

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Beta-lactamase hydrolysis and inhibition studies of the new 1-carbacephem LY163892.

Authors:  R N Jones; A L Barry
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

2.  Computerized microacidimetric determination of beta lactamase Michaelis-Menten constants.

Authors:  R Labia; J Andrillon; F Le Goffic
Journal:  FEBS Lett       Date:  1973-06-15       Impact factor: 4.124

3.  Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors.

Authors:  M D Kitzis; D Billot-Klein; F W Goldstein; R Williamson; G Tran Van Nhieu; J Carlet; J F Acar; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

4.  [Enzyme-substrate behavior. Introduction of the concept of enzymatic stability in the case of beta-lactamases].

Authors:  R Labia
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1974-07-01

5.  Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase.

Authors:  D Sirot; J Sirot; R Labia; A Morand; P Courvalin; A Darfeuille-Michaud; R Perroux; R Cluzel
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

6.  Purification and biochemical properties of Pitton's type 2 beta-lactamase (SHV-1).

Authors:  M Barthélémy; J Peduzzi; C Verchère-Beaur; H Ben Yaghlane; R Labia
Journal:  Ann Inst Pasteur Microbiol (1985)       Date:  1986 Jul-Aug

Review 7.  Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies.

Authors:  J Sirot; C Chanal; A Petit; D Sirot; R Labia; G Gerbaud
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

8.  Kinetic properties of two plasmid-mediated beta-lactamases from Klebsiella pneumoniae with strong activity against third-generation cephalosporins.

Authors:  R Labia; A Morand; K Tiwari; J S Pitton; D Sirot; J Sirot
Journal:  J Antimicrob Chemother       Date:  1988-03       Impact factor: 5.790

9.  In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

10.  The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.

Authors:  H C Neu; N X Chin; K Jules; P Labthavikul
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

  10 in total
  7 in total

1.  Prediction of the evolution of ceftazidime resistance in extended-spectrum beta-lactamase CTX-M-9.

Authors:  J Delmas; F Robin; F Carvalho; C Mongaret; R Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Patterns and mechanisms of beta-lactam resistance among isolates of Escherichia coli from hospitals in the United States.

Authors:  R Cooksey; J Swenson; N Clark; E Gay; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 3.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

Review 4.  Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 5.  Cefetamet pivoxil clinical pharmacokinetics.

Authors:  R A Blouin; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

Review 6.  Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; H M Bryson
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

7.  In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins.

Authors:  B D Jett; D J Ritchie; R Reichley; T C Bailey; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.